title: Daclizumab as induction therapy in kidney and simultaneous pancreas-kidney transplantation.
abstract: Acute rejection still remains a major problem in organ transplantation and is a significant risk factor for chronic rejection, and chronic rejection is one of the most important causes of late graft loss. Current new immunosuppressive drugs such as tacrolimus, rapamycin and mycophenolate mofetil have been developed to reduce acute rejection and to improve renal allograft survival. More recently, antihuman antibodies, either monoclonal or polyclonal, have been developed to use for induction therapy at the time of transplantation or to treat rejection. Daclizumab, a new engineered human immunoglobulin monoclonal antibody to the interleukin-2 receptor a-subunit was approved to prevent acute rejection after solid organ transplantation. Data from clinical trials show daclizumab to be well tolerated in solid organ transplantation. It does not increase the incidence of infection, including cytomegalovirus infection.
authors.affiliation: Division of Transplantation, Department of Surgery, University of Miami School of Medicine, Miami, FL 33101, USA. gciancio@med.miami.edu
authors.forename: G
authors.initials: G
authors.lastname: Ciancio
authors.forename: A
authors.initials: A
authors.lastname: Mattiazzi
authors.forename: J
authors.initials: J
authors.lastname: Miller
authors.forename: G W
authors.initials: GW
authors.lastname: Burke
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077552:Basiliximab; D065095:Calcineurin Inhibitors; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000379:methods / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016035:Pancreas Transplantation / Q000379:methods / Q000502:physiology; D011993:Recombinant Fusion Proteins; D012086:Reoperation; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D065095:Calcineurin Inhibitors; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000077561:Daclizumab; D009173:Mycophenolic Acid